Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Gastrointestinal Cancer

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Lancet

Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM, LEAP-012 investigators

doi: 10.1016/S0140-6736(24)02575-3

Further Publications

Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study

Lancet Gastroenterol Hepatol

Lindfors A, Strandberg R, Hagström H

doi: 10.1016/S2468-1253(24)00313-3

Inflammatory Bowel Disease

Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study

J Crohns Colitis

Loftus EV Jr, D'Haens G, Louis E, Regueiro M, Jairath V, Magro F, Nakase H, Dubcenco E, Lacerda AP, Ford S, Feng T, Duncan B, Fish I, Cunneen C, Anyanwu SI, Aponte F, Griffith J, Blumenstein I

doi: 10.1093/ecco-jcc/jjaf138

Inflammatory Bowel Disease

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study

Lancet Gastroenterol Hepatol

Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S

doi: 10.1016/S2468-1253(25)00017-2

RECOMMENDED

Inflammatory Bowel Disease

Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial

★ 3 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

Lancet Gastroenterol Hepatol

Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, Jairath V, D'Haens G, Kierkuś J, Leong RW, Yarur AJ, Vincent MS, Banerjee A, Chandra DE, Peeva E, Neelakantan S, Hung KE, McBride JM, Bojic D, Lasch K, Schiffman C, Feagan BG

doi: 10.1016/S2468-1253(25)00129-3

Hepatitis

Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis

Hepatology

Souza M, Al-Sharif L, Antunes VLJ, Huang DQ, Loomba R

doi: 10.1097/HEP.0000000000001254

Hepatology

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Am J Gastroenterol

Caviglia GP, Ferro A, D'Ambrosio R, Perbellini R, Lampertico P, Periti G, Valenti L, Ciccioli C, Pennisi G, Petta S, Brodosi L, Petroni ML, Marchignoli F, Pironi L, Sagripanti A, Argenziano ME, Svegliati-Baroni G, Rosso C, Barutta F, Armandi A, Gruden G, Bugianesi E

doi: 10.14309/ajg.0000000000003493

Hepatology

Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease

J Hepatol

Oh JH, Yoon EL, Park H, Lee S, Jo AJ, Cho S, Kwon E, Nah EH, Lee JH, Park JH, Ahn SB, Jun DW

doi: 10.1016/j.jhep.2025.06.005

Related content

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study

Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study

Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial

Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease